A system for tumor heterogeneity evaluation and diagnosis based on tumor markers measured routinely in the laboratory

作者：Liu Hui^*; Liu Rixv; Zhou Xiuying

来源：Clinical Biochemistry, 2015, 48(18): 1241-1245.

DOI：10.1016/j.clinbiochem.2015.07.027

• Tumor heterogeneity
• Evaluation system
• Serum tumor markers
• Tumor heterogeneity index
• Tumor marker index

Objectives: To develop an efficient and reliable approach to estimate tumor heterogeneity and improve tumor diagnosis using multiple tumor markers measured routinely in the clinical laboratory.
Methods: A total of 161 patients with different cancers were recruited as the cancer group, and 91 patients with non-oncological conditions were required as the non-oncological disease group. The control group comprised 90 randomly selected healthy subjects. AFP, CEA, CYFRA, CA125, CA153, CA199, CA724, and NSE levels were measured in all these subjects with a chemiluminescent microparticle immunoassay. The tumor marker with the maximum S/CO value (sample test value: cutoff value for discriminating individuals with and without tumors) was considered as a specific tumor marker (STM) for an individual. Tumor heterogeneity index (THI) = N/P (N: number of STMs; P: percentage of individuals with STMs in a certain tumor population) was used to quantify tumor heterogeneity: high THI indicated high tumor heterogeneity. The tumor marker index (TMI), TMI = STM x (number of positive tumor markers + 1), was used for diagnosis.
Results: The THIs of lung, gastric, and liver cancers were 8.33, 9.63, and 5.2, respectively, while the ROC-areas under the curve for TMI were 0.862, 0.809, and 0.966.
Conclusion: In this study, we developed a novel index for tumor heterogeneity based on the expression of various routinely evaluated serum tumor markers. Development of an evaluation system for tumor heterogeneity on the basis of this index could provide an effective diagnostic tool for some cancers.

• 出版日期2015-12
• 单位大连医科大学